Nuvation Bio
NUVB
4.86
-0.02
-0.41%
Nuvation Bio
US · NUVB
#2898 by market cap
Listed 1970
4.86
-0.02
-0.41%
Live - 5344 symbols - heartbeat 278s ago
· 2026-10-08 08:26
Pre-market
4.81
-1.06%
After-hours
4.95
+1.85%
Overnight
4.82
-0.82%
- Market cap
- 1.71B
- P/E (TTM)i
- -11.05
- P/Bi
- 6.72
- EPSi
- -0.60
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on NUVB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.83, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year +698.96% YoY
Margins
- Gross margin
- 85.22%
- Operating margin
- -338.72%
- Net margin
- -325.31%
Key ratios & quality
- Enterprise valuei
- 1.23B
- Altman Z-Scorei
- 0.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0 | 7.87M | 62.90M |
| Gross profit | -- | -- | -- | 0 | 795.00K | 53.60M |
| Selling & admin expenses | 10.95M | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Research & development | 32.60M | 69.04M | 87.82M | 71.29M | 99.12M | 115.11M |
| Operating profit | -43.55M | -93.32M | -119.73M | -99.82M | -167.56M | -213.06M |
| Pretax profit | -41.66M | -86.85M | -104.20M | -75.80M | -567.94M | -204.63M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -41.66M | -86.85M | -104.20M | -75.80M | -567.94M | -204.63M |
| Basic EPS | 0 | 0 | 0 | 0 | -2 | -1 |
| Diluted EPS | -0.19 | -0.44 | -0.48 | -0.35 | -2.11 | -0.60 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.08M | 4.83M | 13.12M | 41.87M | 83.23M | 31.69M |
| Gross profit | 990.00K | 2.26M | 9.77M | 40.59M | 77.24M | 22.22M |
| Selling & admin expenses | 35.39M | 38.48M | 37.36M | 40.33M | 38.31M | 42.59M |
| Research & development | 24.60M | 27.36M | 28.85M | 34.30M | 35.05M | 30.66M |
| Operating profit | -59.00M | -63.59M | -56.43M | -34.04M | 3.88M | -51.04M |
| Pretax profit | -53.24M | -59.01M | -55.79M | -36.59M | 5.40M | -62.84M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -53.24M | -59.01M | -55.79M | -36.59M | 5.40M | -62.84M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.16 | -0.17 | -0.16 | -0.11 | 0.01 | -0.18 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 220.68M | 772.07M | 667.32M | 616.43M | 526.26M | 571.52M |
| Cash & ST investments | 215.75M | 765.39M | 661.01M | 611.21M | 502.69M | 529.21M |
| Inventory | -- | -- | -- | -- | 0 | 11.41M |
| Total assets | 221.79M | 776.15M | 672.14M | 621.48M | 540.63M | 594.82M |
| Total current liabilities | 6.55M | 16.93M | 13.16M | 13.97M | 58.24M | 82.23M |
| Short-term debt | -- | 863.00K | 1.21M | 1.97M | 7.95M | 7.60M |
| Long-term debt | -- | -- | -- | -- | -- | 47.21M |
| Total liabilities | 6,708,000.00 | 30,154,000.00 | 17,065,000.00 | 16,362,000.00 | 76,838,000.00 | 289,106,000.00 |
| Total equity | 215.08M | 746.00M | 655.08M | 605.12M | 463.79M | 305.72M |
| Retained earnings | -75.96M | -162.80M | -267.00M | -342.80M | -910.74M | -1.12B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 475.57M | 623.21M | 577.53M | 571.52M | 591.53M | 726.43M |
| Cash & ST investments | 461.68M | 607.72M | 549.05M | 529.21M | 533.73M | 660.96M |
| Inventory | 14.00K | 552.00K | 5.71M | 11.41M | 15.84M | 19.90M |
| Total assets | 492.49M | 647.23M | 601.56M | 594.82M | 610.24M | 744.50M |
| Total current liabilities | 52.77M | 66.36M | 68.13M | 82.23M | 79.52M | 86.76M |
| Short-term debt | 7.57M | 7.39M | 7.49M | 7.60M | 7.63M | 7.61M |
| Long-term debt | -- | 46.97M | 47.09M | 47.21M | 47.33M | 242.62M |
| Total liabilities | 73,029,000.00 | 274,318,000.00 | 275,679,000.00 | 289,106,000.00 | 290,677,000.00 | 490,639,000.00 |
| Total equity | 419.46M | 372.91M | 325.88M | 305.72M | 319.56M | 253.86M |
| Retained earnings | -963.98M | -1.02B | -1.08B | -1.12B | -1.11B | -1.17B |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -36.53M | -68.19M | -96.11M | -68.00M | -130.41M | -173.43M |
| Depreciation & amortization | 103.00K | 184.00K | 199.00K | 222.00K | 683.00K | 1.74M |
| Free cash flow | -36.67M | -68.47M | -96.48M | -68.07M | -130.58M | -181.78M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 135.66M | -- | -- | -- | -- | -- |
| Ending cash balance | 29.76M | 132.42M | 101.10M | 42.65M | 35.72M | 164.09M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -42.63M | -48.18M | -52.89M | -29.73M | 5.07M | -42.97M |
| Depreciation & amortization | 310.00K | 356.00K | 534.00K | 539.00K | 536.00K | 536.00K |
| Free cash flow | -42.70M | -48.36M | -60.90M | -29.82M | 5.02M | -43.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 47.98M | 247.97M | 98.90M | 164.09M | 125.39M | 258.60M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -19.37 | -18.07 | -14.87 | -12.03 | -106.27 | -53.18 |
| ROA %i | -18.78 | -17.41 | -14.39 | -11.72 | -97.74 | -36.04 |
| ROIC %i | -20.27 | -18.61 | -15.85 | -15.83 | -109.94 | -50.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -34.12 | -40.89 |
| EBIT margin %i | -- | -- | -- | -- | -7,209.42 | -303.56 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 33.69 | 45.62 | 50.70 | 44.11 | 9.04 | 6.95 |
| Quick ratioi | 33.10 | 45.40 | 50.41 | 44.00 | 8.91 | 6.67 |
| Debt / assetsi | 0.00 | 0.39 | 0.63 | 0.64 | 1.65 | 9.64 |
| LT debt / equityi | -- | 0.29 | 0.47 | 0.34 | 0.21 | 16.27 |
| Interest coveragei | -- | -- | -- | -- | -1,664.51 | -13.96 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -119.66 | -64.40 | -52.49 | -53.18 | -39.51 | -47.81 |
| ROA %i | -109.69 | -32.67 | -37.08 | -36.04 | -26.48 | -21.53 |
| ROIC %i | -122.76 | -64.08 | -51.84 | -50.82 | -36.37 | -30.79 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -5,530.60 | -1,408.67 | -786.53 | -303.56 | -87.84 | -72.49 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.01 | 9.39 | 8.48 | 6.95 | 7.44 | 8.37 |
| Quick ratioi | 8.85 | 9.26 | 8.26 | 6.67 | 7.04 | 7.98 |
| Debt / assetsi | 2.32 | 8.92 | 9.57 | 9.64 | 9.37 | 33.87 |
| LT debt / equityi | 0.92 | 13.51 | 15.36 | 16.27 | 15.50 | 96.32 |
| Interest coveragei | -1,534.15 | -295.63 | -29.64 | -13.96 | -6.18 | -4.62 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Oncology development activities100.00%
Quote time 2026-10-08 08:26:01 · For reference only, not investment advice and not tailored to your situation.